Following neoadjuvant chemotherapy, patients experience pathological complete response (pCR) and may exhibit improved survival results (5, 6).The selection of neoadjuvant therapy for breast cancer is determined by the patient’s physiological condition, such as age, menopausal status, underlying diseases, and the pathological characteristics of the cancer, including tumor size, lymph node involvement, hormone receptor status, HER2 expression, and Ki-67 expression (7). The gene discussed is NR4A1; the disease is breast carcinoma.